These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension. Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448 [TBL] [Abstract][Full Text] [Related]
10. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways. Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637 [TBL] [Abstract][Full Text] [Related]
11. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension. Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121 [TBL] [Abstract][Full Text] [Related]
12. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Wang S; Yu M; Zheng X; Dong S Drug Deliv; 2018 Nov; 25(1):1898-1909. PubMed ID: 30442035 [TBL] [Abstract][Full Text] [Related]
13. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE Respiration; 2017; 94(1):26-37. PubMed ID: 28494463 [TBL] [Abstract][Full Text] [Related]
14. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Dranitsaris G; Mehta S Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension. Swisher JW; Elliott D Respir Med Case Rep; 2017; 20():45-47. PubMed ID: 27942445 [TBL] [Abstract][Full Text] [Related]
16. [Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia]. Shmalts AA; Gorbachevsky SV Ter Arkh; 2020 Dec; 92(12):80-85. PubMed ID: 33720578 [TBL] [Abstract][Full Text] [Related]
17. Macitentan in the treatment of pulmonary arterial hypertension. Zebadúa R; Hernández-Pérez AP; García A; Zayas N; Sandoval J; López J; Pulido T Future Cardiol; 2021 Jan; 17(1):49-58. PubMed ID: 32677463 [TBL] [Abstract][Full Text] [Related]
18. Update on pharmacotherapy for pulmonary hypertension. Prior DL; Adams H; Williams TJ Med J Aust; 2016 Sep; 205(6):271-6. PubMed ID: 27627939 [TBL] [Abstract][Full Text] [Related]
19. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Sulica R; Fenton R; Cefali F Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969 [TBL] [Abstract][Full Text] [Related]